Zenas BioPharma
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · Massachusetts, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
1000 Winter St Ste 1200, Waltham, Massac...Phone Number
(857) 271-2954Website
www.zenasbio.comRevenue
<$5 MillionStock Symbol
ZBIOIndustry
About Zenas BioPharma
Zenas BioPharma is dedicated to developing therapies for patients with autoimmune diseases, aiming to address significant unmet medical needs and transform their lives. The company is advancing its investigational drug, Obexelimab, which targets B cell activity to help manage various autoimmune conditions. They prioritize understanding the experiences of patients and caregivers to create impactful therapies. Zenas BioPharma is committed to leading in the field of autoimmune disease treatment through its experienced team and innovative approach.Explore more
Zenas BioPharma Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Compare Similar Companies to Zenas BioPharma
Compare insights from companies similar to Zenas BioPharma, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
$50.7M
51-200
Private
-
1999
AO
Aram OganesianVice President, Clinical Pharmacology & Nonclinical Development
<$5M
51-200
Private
$170M
2019
Zenas BioPharma Tech Stack
A closer look at the technologies used by Zenas BioPharma
Top Manufacturing Companies
See more top companies
Frequently Asked Questions Regarding Zenas BioPharma
Sign Up For FreeTo access detailed company insights
Zenas BioPharma is dedicated to developing therapies for patients with autoimmune diseases, aiming to address significant unmet medical needs and transform their lives. The company is advancing its investigational drug, Obexelimab, which targets B cell activity to help manage various autoimmune conditions. They prioritize understanding the experien... Read More
